Ownership history in RGM Capital, LLC Β· 4 quarters on record
This page tracks every 13F SEC filing in which RGM Capital, LLC reported a position in BIO-TECHNE CORP (TECH). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π RGM Capital, LLC underperformed the S&P 500 by β26.0% annually on this TECH position. Timing score: 67% (2/3 decisions correct). Average cost basis: $54.52. Maximum drawdown during holding period: β12.1%.
β Significantly underperformed the S&P 500 by 26.0% ann.
3 quarters analyzed
β
Decent timing β more right than wrong on entries and exits.
2 of 3 add/trim decisions correct
Best entry: $51.24 (2025 Q2) Β· Worst: $58.29 (2025 Q1)
π No drawdown exceeding 20% during the holding period β exceptionally stable.
3 adds Β· 1 trim. Bought during 1 of 1 down-price quarters. π Consistently bullish β fund kept accumulating this position.
π RGM Capital, LLC has been actively increasing its TECH allocation β a bullish signal from insiders.
Currently 6.14% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size